Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1ATTRACTION-3, 20191KEYNOTE-181, 20201ESCORT, 2020camrelizumab alone vs. nivolumab alone 0.92 [0.68; 1.25]0.92 [0.68;1.25]camrelizumab alone vs. nivolumab alone 0.92 [0.68; 1.25]camrelizumab alone vs. pembrolizumab alone 0.80 [0.61; 1.05]0.80 [0.61;1.05]camrelizumab alone vs. pembrolizumab alone 0.80 [0.61; 1.05]camrelizumab alone vs. Standard of Care (SoC) camrelizumab alone better 0.71 [0.57; 0.88]0.71 [0.57;0.88]camrelizumab alone vs. Standard of Care (SoC) camrelizumab alone better 0.71 [0.57; 0.88]nivolumab alone vs. camrelizumab alone 1.08 [0.80; 1.47]1.08 [0.80;1.47]nivolumab alone vs. camrelizumab alone 1.08 [0.80; 1.47]nivolumab alone vs. pembrolizumab alone 0.87 [0.66; 1.14]0.87 [0.66;1.14]nivolumab alone vs. pembrolizumab alone 0.87 [0.66; 1.14]nivolumab alone vs. Standard of Care (SoC) nivolumab alone better 0.77 [0.62; 0.96]0.77 [0.62;0.96]nivolumab alone vs. Standard of Care (SoC) nivolumab alone better 0.77 [0.62; 0.96]pembrolizumab alone vs. camrelizumab alone 1.25 [0.96; 1.64]1.25 [0.96;1.64]pembrolizumab alone vs. camrelizumab alone 1.25 [0.96; 1.64]pembrolizumab alone vs. nivolumab alone 1.16 [0.88; 1.52]1.16 [0.88;1.52]pembrolizumab alone vs. nivolumab alone 1.16 [0.88; 1.52]pembrolizumab alone vs. Standard of Care (SoC) 0.89 [0.75; 1.05]0.89 [0.75;1.05]pembrolizumab alone vs. Standard of Care (SoC) 0.89 [0.75; 1.05]Standard of Care (SoC) vs. camrelizumab alone camrelizumab alone better 1.41 [1.14; 1.74]1.41 [1.14;1.74]Standard of Care (SoC) vs. camrelizumab alone camrelizumab alone better 1.41 [1.14; 1.74]Standard of Care (SoC) vs. nivolumab alone nivolumab alone better 1.30 [1.04; 1.62]1.30 [1.04;1.62]Standard of Care (SoC) vs. nivolumab alone nivolumab alone better 1.30 [1.04; 1.62]Standard of Care (SoC) vs. pembrolizumab alone 1.12 [0.95; 1.33]1.12 [0.95;1.33]Standard of Care (SoC) vs. pembrolizumab alone 1.12 [0.95; 1.33]Standard of Care (SoC)nivolumab alonepembrolizumab alonecamrelizumab alonedirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)nivolumab alonepembrolizumab alonecamrelizumab alone
Standard of Care (SoC)---1.30
1.04; 1.62		1.12
0.95; 1.33		1.41
1.14; 1.74
nivolumab alone0.77
0.62; 0.96		---0.87
0.66; 1.14		1.08
0.80; 1.47
pembrolizumab alone0.89
0.75; 1.05		1.16
0.88; 1.52		---1.25
0.96; 1.64
camrelizumab alone0.71
0.57; 0.88		0.92
0.68; 1.25		0.80
0.61; 1.05		---

pathologies: 148 - treatments: 661 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons